#LegendNews: At @EHA_Hematology, we presented Phase 1 data for LB2501, our investigational in vivo CD19/CD20 dual-targeting CAR-T therapy. Results showed clinical activity after a single infusion and a favorable safety profile to date. Read more: https://t.co/0GOB570JoZ
Heading to #EHA2026? Visit us at booth A5.05 to learn more about our latest advances in #CellTherapy and ongoing, innovative efforts across oncology. We look forward to connecting with the hematology community to share the science behind our work.
@EHA_Hematology
#LegendNews at #EHA2026. We’ll present initial Phase 1 LB2501 data in relapsed/refractory B-cell NHL in a late-breaking oral presentation. The abstract highlights encouraging clinical activity and a favorable safety profile.
Learn more: https://t.co/1lTEqrcu00
@EHA_Hematology
#LegendNews: We’re excited to share our late-breaking overall survival data at the @Myeloma_Society Annual Meeting.
We strive to transform the treatment landscape with a one-time treatment option for those battling #MultipleMyeloma: https://t.co/pO253Tinli
Requesting FDA & CDC to provide guidance on these 2 questions that many concerned citizens are asking
1. Should patients on chemotherapy/immunosuppression get neutralizing antibodies checked, and if negative get a booster?
2. Should people who got single dose J&J get a booster?